Business
Axogen focuses on peripheral nerve repair, with Avance nerve products and a broader repair portfolio.
Axogen grew revenue 20%, but losses widened, free cash flow turned negative, and insider activity was sales-only.
The read at a glance✓ Audited against SEC data
- Business mix — Peripheral nerve repair productsNote
- Revenue — Revenue rose 20.2%OK
- Losses — Net loss widened to $15.7MWatch
- Cash — Free cash flow fell to -$2.9MWatch
- Balance sheet — Equity rose; debt edged upNote
- Insiders — 0 buys / 31 sellsWatch
- Accounting — Altman-Z distress; earnings-quality safeWatch
Leadership changes
From Axogen, Inc.'s own filings, the day they're filed.
- Michael Dale · Chief Executive Officer · appointmenteff. 2024-08-09
- Mike Donovan · President · departureeff. 2024-03-22
- Kathy Weiler · President · appointmenteff. 2023-12-20
Latest filings
- 10-Q · Quarterly report2026-07-29
- 8-K · Company announcement2026-07-29
- 8-K · Company announcement2026-06-23
- DEF 14A · Annual proxy (pay & governance)2026-04-29
- 10-Q · Quarterly report2026-04-28
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Axogen, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.